Arcturus Therapeutics (NASDAQ:ARCT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Arcturus Therapeutics (NASDAQ:ARCT) from a sell rating to a hold rating in a research report released on Saturday morning,Wall Street Zen reports.

Several other analysts have also commented on the company. Roth Capital reaffirmed a “buy” rating and issued a $41.00 price target on shares of Arcturus Therapeutics in a research note on Wednesday, September 2nd. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Thursday. Citigroup raised Arcturus Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the company from $8.00 to $20.00 in a report on Thursday. BTIG Research cut their price objective on Arcturus Therapeutics from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.43.

Arcturus Therapeutics Trading Up 4.4%

ARCT opened at $14.46 on Friday. The stock has a market cap of $410.95 million, a PE ratio of -4.37 and a beta of 2.48. Arcturus Therapeutics has a 1 year low of $5.50 and a 1 year high of $24.17. The stock’s 50 day simple moving average is $11.38 and its 200-day simple moving average is $8.89.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Friday, August 7th. The biotechnology company reported ($0.84) EPS for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.16. The business had revenue of $2.96 million during the quarter, compared to analyst estimates of $3.11 million. Arcturus Therapeutics had a negative return on equity of 46.54% and a negative net margin of 317.62%. Equities analysts forecast that Arcturus Therapeutics will post -3.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of large investors have recently modified their holdings of ARCT. BlackRock Inc. bought a new position in Arcturus Therapeutics in the 2nd quarter worth approximately $17,566,000. Sumitomo Mitsui Trust Group Inc. lifted its holdings in Arcturus Therapeutics by 12.9% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,288,935 shares of the biotechnology company’s stock worth $17,671,000 after buying an additional 262,347 shares in the last quarter. Heartland Advisors Inc. bought a new position in Arcturus Therapeutics in the 2nd quarter valued at $1,474,000. Bank of New York Mellon Corp bought a new position in Arcturus Therapeutics in the 2nd quarter valued at $540,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Arcturus Therapeutics in the 2nd quarter valued at $394,000. 94.54% of the stock is currently owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a biotechnology company focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. The company’s platform includes LUNAR, a lipid-mediated delivery system designed to transport nucleic acid medicines into targeted cells, and STARR, a self-amplifying mRNA technology intended to produce therapeutic proteins from relatively small doses of RNA.

Arcturus is developing RNA-based candidates for rare diseases, infectious diseases, and other conditions.